Table 2.

[In-vitro] - Peptides from prepared hydrolysate

Sl. No.	Protein fragments	Peptide sequence identified	Molecular weight (Da)	Reported biological activity of identified peptides	Reference
1	β-lg f (1–8)	IIVTQTMK	932.54	ACE-inhibitory	(Chobert et al. 2005)
2	β-lg f (21–40)	SLAMAASDISLLDAQSAPLR	2030.30	ACE-inhibitory, Immunomodulatory	(Chobert et al. 2005; Rodriguez-carrio et al. 2014)
3	β-lg f (25–40)	AASDISLLDAQSAPLR	1626.68	Bactericidal	(Pellegrini et al. 2001)
4	β-lg f (33–40)	DAQSAPLR	855.47	ACE-inhibitory	(Pihlanto-leppala et al. 2000)
5	β-lg f (41–47)	VYVEELK	878.55	Antioxidant	(Hernandez-ledesma et al. 2005)
6	β-lg f (48–60)	PTPEGDLEILLQK	1452.87	-	-
7	β-lg f (78–82)	IPAVF	545.36	ACE-inhibitory	(Konard et al. 2014)
8	β-lg f (79–83)	PAVFK	560.31	ACE-inhibitory	(Dalsgaard et al. 2008)
9	β-lg f (78–83)	IPAVFK	673.47	ACE-inhibitory, Antimicrobial	(Chobert et al. 2005; Pellegrini et al. 2001)
10	β-lg f (84–91)	IDALNENK	914.60	ACE-inhibitory, Immunomodulatory	(Chobert et al. 2005; Rodriguez-carrio et al. 2014)
11	β-lg f (92–100)	VLVLDTDYK	1064.66	ACE-inhibitory, Antimicrobial	(Pihlanto-leppala et al. 2000)
12	β-lg f (94–100)	VLDTDYK	852.48	ACE-inhibitory	(Pihlanto-leppala et al. 2000)
13	β-lg f (125–135)	TPEVDDEALEK	1244.65	ACE inhibitory	(Roufik et al. 2006)
14	β-lg f (127–135)	EVDDEALEK	1046.59	-	-
15	β-lg f (139–148)	ALKALPMHIR	1164.77	Antioxidant	(Hernandez-ledesma et al. 2005)
16	β-lg f (142–148)	ALPMHIR	836.53	ACE-inhibitory, Antioxidant	(Mullally et al. 1997)